LeapRx
Program Details
Lena Gray, P.T. &
Baby Development Expert
ADVANCE YOUR DISCOVERIES INTO THERAPIES WITH LeapRx
Empire Discovery Institute (EDI) and global pharmaceutical company Novo Nordisk have formed LeapRx, a collaborative research initiative that co-invests in, incubates, and accelerates novel drug discovery programs in cardio-metabolic diseases and rare blood disorders. Programs of interest include diabetes (type 1 and type 2), obesity, cardiovascular disease, NASH, chronic kidney disease, and rare blood disorders. LeapRx provides:
•
Access to funding, technical capabilities, and guidance from pharmaceutical industry experts
•
Customized project teams dedicated to ensuring scientific and operational success
•
Milestone-based workplans co-developed by pharma experts and your institution designed to add patient and commercial value
•
A clearly defined commercial path and exit strategy
FUNDING AND TIMELINE
Total funding of up to $10M over five years for successful programs advancing through the developmental pipeline. The financial commitment expected to support the first year of each selected program is $250,000.
ELIGIBILITY
LeapRx provides financial support and pharmaceutical industry expertise to aid researchers affiliated with EDI's core academic research labs at the University of Rochester, University at Buffalo, and Roswell Park Comprehensive Cancer Center. Premier academic research institutions not affiliated with EDI's core labs are also welcome to apply to LeapRx through their technology transfer offices.
FOR MORE INFORMATION, PLEASE CONTACT
Molly Mesko, Director of Portfolio Development and Alliance Management
E-mail: meskom@discoveredi.org
